Levels of serum CA125 were significantly elevated in women with ovarian cancer [233.4 U/mL (IQR: 92.2–424.1)] compared to those without [13.6 U/mL (IQR: 9.3–19.0)]; however, there was no significant difference in biomarker levels between low- and high-grade disease [151.5 U/mL (IQR: 89.9–424.1) vs. 262.9 U/mL (IQR: 154.9–14,407.7), p = 0.25] or early- and advanced-stage disease [156.3 U/mL (IQR: 89.9–355.4) vs. 14,356.5 U/mL (IQR: 203.2–30,305.0), p = 0.11]. Here, MUC16 is linked to ovarian cancer.